



We
Collect
the **Cells**
you search for

CellCollector



GILUPIs fishing rod is the CellCollector



Which cells are important in cancer?

Human blood contains about 5 billion cells per in one milliliter. In the blood of cancer patients, few tumor-derived cells can be detected among this tremendous number of normal cells. These cells detach from the primary tumor, circulate in the blood and may cause the formation of metastases.

Why are these cells so informative?

In recent years these circulating tumor cells (CTCs) have been shown to have the potential to be an additional and useful source of information that can support decisions in the therapy of cancer. Changes in the number of CTCs can be used for monitoring the effects of a therapy and for optimizing the therapy. In addition, CTCs reflect molecular alterations of the tumor in the course of the disease and thus give important information for the treating physician. This information enables the physician to adapt a therapy quickly to the individual needs of a patient and to choose the optimal therapy.

How is GILUPI isolating CTCs?

The GILUPI GmbH has developed a CellCollector, allowing a low-risk and efficient way to "fish" CTCs from the blood circulation.

GILUPIs fishing rod is the Cellcollector

The CellCollector works by insertion (2cm) into the vein of an arm via a thin infusion cannula. The CellCollector remains in the blood stream for 30 minutes, is then removed and the attached CTCs are analyzed.

How was our method validated?

Safety and specificity of the CellCollector have been tested in several national and international clinical trials with healthy volunteers while its functionality was examined with breast, lung and prostate cancer patients.

CTCs were found in more than 85% percent of the cancer patients who participated in these studies.

Whom to contact if interested?

If you are interested in this process, please contact your treating physician directly.

Why are CTCs important for you?

- ✓ CTCs provide the doctor with decisive information on the status of the tumor disease and the results of the treatment.
- ✓ This information allows an immediate response to the therapy process (e.g. preventing unnecessary cycles of a therapy).
- ✓ Non-effective treatments can be detected much earlier.
- ✓ Enables earlier and more accurate predictions.

What are the advantages of the CellCollector?

- ✓ In comparison to existing methods, the GILUPI technique is an efficient and cost-effective way to "capture" circulating tumor cells.
- ✓ The CellCollector of GILUPI can be applied by any physician.
- ✓ The application of this method can easily be combined with outpatient / inpatient treatment stays.

In addition, the method is of

- ✓ minor stress for the patient
- ✓ and of low risk in its application



GILUPI GmbH

Based on unique patented technology since its founding in 2006, GILUPI has developed new diagnostic products for the *in vivo* isolation of rare cells from circulating blood. The focus of GILUPI is on prenatal and cancer diagnostic markets.

The GILUPI method is a novel technology platform which is expected to have a decisive impact on the cell-based molecular diagnostic market.

GILUPI started as a small research department in Potsdam. Today, GILUPI is a medium-sized company that runs clinical trials and has its own quality management and marketing. GILUPI's own production facility has been established at a second site in Greifswald.

CEO

Dr. Klaus Lücke

CMO

Dr. Nils G. Morgenthaler

Headquarter

Am Mühlenberg 11

14476 Potsdam

Germany

Tel.: +49 (0) 331-5818478-2

Fax: +49 (0) 331-5818478-0

info@gilupi.com

www.gilupi.com

Branch

Walther-Rathenau-Str. 49 A

17489 Greifswald

Germany



Edition 001